Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha Interferon in chronic lymphocytic leukaemia.

E Montserrat1, N Villamor, A Urbano-Ispizua

  • 1Postgraduate School of Hematology Farreras Valenti, Hospital Clinic, University of Barcelona, Spain.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1991
PubMed
Summary

Alpha interferon shows promise for chronic lymphocytic leukemia (CLL) patients, particularly those untreated or in early stages. Low doses are effective and tolerable, though responses are often temporary.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor.

Journal for immunotherapy of cancer·2019
Same author

Development of adaptive immune effector therapies in solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

Bone marrow transplantation·2016
Same author

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes.

Bone marrow transplantation·2016
Same author

Adult T-cell Leukemia in a Chilean Resident in Spain: Long-Lasting Remission after 2-Deoxycoformycin Treatment.

Leukemia & lymphoma·2016

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • The efficacy of alpha interferon (IFN-α) in chronic lymphocytic leukemia (CLL) remains incompletely defined.
  • Existing data suggest differential responses based on patient treatment history and disease stage.

Purpose of the Study:

  • To evaluate the role and effectiveness of alpha interferon in managing chronic lymphocytic leukemia.
  • To explore optimal dosing strategies and potential combination therapies involving alpha interferon.

Main Methods:

  • Review of existing studies on alpha interferon treatment in CLL patients.
  • Analysis of response rates in relation to prior chemotherapy and disease stage.
  • Assessment of toxicity profiles and immunoglobulin/granulocyte level changes.

Related Experiment Videos

Main Results:

  • Higher response rates observed in previously untreated patients and those with early-stage CLL.
  • Responses are typically transient, with rare complete remissions; clonal remission induction is unconfirmed.
  • Low-dose alpha interferon (e.g., 2 MU/m² thrice weekly) is effective and tolerable, comparable to high doses.

Conclusions:

  • Alpha interferon demonstrates activity in CLL, particularly in specific patient subgroups.
  • Further research is warranted for combination therapies and strategies to prolong response duration.
  • Low-dose regimens are recommended due to comparable efficacy and improved tolerability.